GLP-1 receptor agonists × quality of life & behaviour

TrialThe Journal of clinical endocrinology and metabolism2025

Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.

Mojca Jensterle et al.PubMed ↗Publisher ↗

  • Semaglutide 1.0 mg once weeklylooks good hereHigher overall taste recognition score.Randomised, small.

What the trial testedrandomised · 30 people · 2025

Randomised vs placebo

Probably raised overall taste recognition score

+2.50points+1.70 to +3.30

semaglutide 1.0 mg once weekly vs placebo

As reported

difference 2.5 points, 95% CI 1.70–3.30

Who was studied, and how

30people with obesity, in this paper

The trial randomly assignedassigned by chance

semaglutide 1.0 mg once weekly
placebo

Probably raised overall taste recognition score+2.50

randomised

the abstract, start to end

an estimated treatment difference of 2.5 points (95% CI, 1.7-3.3).

← favours treatmentfavours comparator →
could be chance
Overall taste recognition scoresemaglutide 1.0 mg once weekly vs placebo
2.51.70–3.30
GLP-1 receptor agonistsQuality of life & behaviour

GLP-1 receptor agonists × quality of life & behaviourhelps?mixed

unlikelylikely
0.440.37 without it
← favours comparatorfavours treatment →
this papermore certainless certain
1 / 6

6 papers cite it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 40341357